0000950170-24-032213.txt : 20240315 0000950170-24-032213.hdr.sgml : 20240315 20240315161909 ACCESSION NUMBER: 0000950170-24-032213 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240314 FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PAPADOPOULOS STELIOS CENTRAL INDEX KEY: 0001202098 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35670 FILM NUMBER: 24755044 MAIL ADDRESS: STREET 1: 3 SOMERSET DRIVE SOUTH CITY: GREAT NECK STATE: NY ZIP: 11020 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Regulus Therapeutics Inc. CENTRAL INDEX KEY: 0001505512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 264738379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4224 CAMPUS POINT COURT STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-202-6300 MAIL ADDRESS: STREET 1: 4224 CAMPUS POINT COURT STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-03-14 0001505512 Regulus Therapeutics Inc. RGLS 0001202098 PAPADOPOULOS STELIOS C/O REGULUS THERAPEUTICS INC. 4224 CAMPUS POINT COURT #210 SAN DIEGO CA 92121 true false false false false Common Stock 2024-03-14 4 A false 250000 1.60 A 978388 D The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated March 11, 2024, with a closing date of March 14, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof. Christopher Aker, Attorney in Fact 2024-03-15